GlassScriptPhysician profile
Andrew W Foret
NPI 1336710755
$7,936.35
in general payments reported to CMS, 2019-2025
14 companies · $5,358 in 2025
The $5,358 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $329 · 2022: $310 · 2023: $811 · 2024: $1,128 · 2025: $5,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $5,000 · Food and Beverage: $2,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $5,000.00 |
| Food and Beverage | $2,296.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,000.00 | 2025 | Synchromedii |
| Teva Pharmaceuticals USA, INC. | $654.17 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $604.72 | 2021-2024 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $405.76 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $330.99 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $309.41 | 2021-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Otsuka America Pharmaceutical, INC. | $165.32 | 2023-2024 | Abilify Asimtufii, Nuedexta, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $119.60 | 2023-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $95.21 | 2021-2022 | |
| Abbvie INC. | $81.36 | 2024-2025 | |
| Indivior INC. | $70.97 | 2024 | Perseris, Sublocade |
| Janssen Pharmaceuticals, INC | $44.44 | 2024 | Invega Sustenna |
| Avanir Pharmaceuticals, INC. | $36.69 | 2022 | |
| Stryker Corporation | $17.71 | 2023 | Procuity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Foret listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.